Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBP-301 and Pembrolizumab in Esophagogastric Adenocarcinoma
NCT06340711Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of suratadenoturev in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Weill Cornell Medicine. Started Apr 2024; status: recruiting.
02
Drugs
suratadenoturev
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06340711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340711.